Q3 2025 Resmed Inc Earnings Call Transcript
Key Points
- ResMed Inc (RMD) reported strong financial performance with an 8% increase in group revenue, reaching $1.29 billion for Q3 fiscal year 2025.
- The company achieved gross margin expansion, increasing by 140 basis points to 59.9%, driven by manufacturing and logistics efficiencies.
- ResMed Inc (RMD) maintained a disciplined approach to investments, allocating 6% to 7% of revenues into research and development, which is a key growth driver.
- The company is expanding its manufacturing footprint in the US with a new facility in Calabasas, California, which will double its current manufacturing capacity.
- ResMed Inc (RMD) continues to innovate with the launch of new products like NightOwl and VPAP Tx, enhancing its digital health ecosystem and expanding its market reach.
- ResMed Inc (RMD) faces challenges with sleep lab backlogs, which are at all-time highs, potentially impacting the speed of patient diagnosis and treatment.
- The company is navigating a complex global trade environment, particularly concerning tariffs, although it has secured exemptions for its products.
- There is uncertainty in the market due to geopolitical challenges and potential impacts from US tariffs, which could affect financial results.
- ResMed Inc (RMD) is investing heavily in demand generation and brand development, which requires careful management to ensure a positive return on investment.
- The company faces competition in the market, particularly from other diagnostic and treatment providers, which could impact its market share and growth.
Greetings, and welcome to the Q3 fiscal year 2025 ResMed earnings conference call. My name is Kevin, and I'll be your operator for today's call. (Operator Instructions) And also, please note this conference call is being recorded. (Operator Instructions) Let me hand the call over to ResMed's Chairman and CEO, Mick Farrell; for a brief introduction of Sally Schwartz, who recently joined the company as Chief Investor Relations Officer. Mick, please go ahead.
Thank you, Kevin. I'm very excited to have Sally join the ResMed team, our newest ResMedian. She joined us earlier this week and brings more than two decades of experience across capital markets, health care and technology.
We look forward to Sally helping us to take Investor Relations to the next level here at ResMed, providing clarity, transparency and long-term alignment amongst current and future investors and all of our stakeholders. So Salli, we're thrilled to have you on board.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
